Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006

AIDS

Volumn 24, Issue 8, 2010, Pages 1203-1212

  Wheeler, William H ^a   Ziebell, Rebecca A ^b   Zabina, Helena ^c   Pieniazek, Danuta ^a   Prejean, Joseph ^a   Bodnar, Ulana R ^d   Mahle, Kristen C ^a   Heneine, Walid ^a   Johnson, Jeffrey A ^a   Hall, H Irene ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ginn Group Inc   (United States)

^c Business Computer Applications   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Drug resistance; HIV 1; HIV 1 subtype; Surveillance; Transmission; United States

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; UNITED STATES; VIRUS MUTATION;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PREVALENCE; RNA, VIRAL; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; UNITED STATES; VIRAL LOAD;

EID: 77951877448     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283388742     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 128751297)
2. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394. (Pubitemid 34851830)
3. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180. (Pubitemid 38757188)
4. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007; 8:1-8. (Pubitemid 46542904)
5. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
6. Wheeler W, Mahle K, Bodnar U, Pienaizek D, Kline R, Hall I, et al. Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. In: 14th Conference on Retro-viruses, Opportunistic, Infections, Los Angeles, CA, 2007.
7. HIV-1 strain and primary drug resistance in Canada: surveillance report to March 31, 2005: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2006.
8. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004; 9:695-702. (Pubitemid 39434332)
9. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22:625-635.
10. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285 (Pubitemid 351920631)
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-in-fected adults and adolescents. Department of Health and Human Services. November 3, 208; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoles-centGL.pdf. [Accessed 23 July 2009]
12. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petro-poulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188. (Pubitemid 34755278)
13. Leitner T, Korber B, Daniels M, Calef C, Foley B. HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. In Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, et al., editors. HIV Sequence Compendium 2005. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2005. pp. 41-48.
14. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42:86-90. (Pubitemid 43947951)
15. Sides TL, Akinsete O, Henry K, Wotton JT, Carr PW, Bartkus J. HIV-1 subtype diversity in Minnesota. J Infect Dis 2005; 192:37-45. (Pubitemid 40863855)
16. Lin HH, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, et al. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr 2006; 41:399-404. (Pubitemid 43756154)
17. Abbott Molecular. Viroseq-HIV-1 Genotyping Program. http://www. abbottmolecular.com/ViroSeqHIV1GenotypingSystem-1079.aspx. [Accessed 11 June 2009]
18. Stanford University HIV Drug Resistance Database Team. Sierra: The Stanford HIV Web Service (Beta Version). http://hivdb.-stanford.edu/pages/ webservices/. [Accessed 11 June 2009]
19. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303. (Pubitemid 36150389)
20. GeneStudio Inc. GeneStudio. Version 2.1.2.3, 2009. http://www.genestudio. com/genestudio.htm. [Accessed 11 June 2009]
21. Felsenstein J. PHYLIP Version 3.65, 2008. http://evolution.gen-etics. washington.edu/phylip.html. [Accessed 11 June 2009]
22. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160. (Pubitemid 28565356)
23. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724.
24. Stanford University HIV Drug Resistance Database Team. Surveillance Drug Resistance Mutations (SDRM) Worksheet. http://hivdb.stanford.edu/cgi-bin/ AgMutPrev.cgi. [Accessed 23 July 2009]
25. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21:1035-1039. (Pubitemid 46684335)
26. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr 2008; 49:196-204.
27. Novak RM, ChenL, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40:468-474. (Pubitemid 40216518)
28. Weidle PJ, Ganea CE, Irwin KL, Pieniazek D, McGowan JP, Olivo N, et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis 2000; 181:470-475. (Pubitemid 30131812)
29. Jayaraman GC, Gleeson T, Rekart ML, Cook D, Preiksaitis J, Sidaway F, et al. Prevalence and determinants of HIV-1 subtypes in Canada: enhancing routinely collected information through the Canadian HIV Strain and Drug Resistance Surveillance Program. Can Commun Dis Rep 2003; 29:29-36.
30. Bennett D. HIV [corrected] genetic diversity surveillance in the United States. J Infect Dis 2005; 192:4-9. (Pubitemid 40863849)
31. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
32. Malone N, KBaluja K, Costanzo J, Davis C. The Foreign-Born Population: Census 2000 Brief. In U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau; 2003.
33. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.